Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

In this randomized, non-comparative phase 2 trial, chemotherapy could be omitted in HER2-positive early breast cancer according to FDG-PET response and pathologic complete response. After a median 5.6 years of follow-up, 5-year invasive disease-free survival was 89.5% (95% CI 85.7-93.4) in group B (n=267). Exploratory analyses found that detectable ctDNA at baseline or during treatment was associated with inferior invasive disease-free survival, and that ctDNA clearance correlated with higher pathologic complete response rates and improved long-term outcomes. The abstract does not name the ctDNA assay.

Nature MedicinePubMed 42957778DOI 10.1038/s41591-026-04723-w